MedTrace Logo

The Effects of Intravitreal Ozurdex Implant in DME

NCT03475407 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-03-23

No results posted yet for this study

Summary

Intravitreal Ozurdex implant therapy improves visual outcome and OCT findings. The purpose of this study is that these results are correlated with the change of cytokine level known to be increased in DME patients.

Conditions

Interventions

DRUG

Ozurdex intravitreal injection

1. Ozurdex intravitreal injection and Antreior Chamber(AC) paracentesis at baseline 2. AC paracentesis at 6 wk 3. intravitreal Ozurdex injection and AC paracentesis at 18wk or 24wk

Sponsors & Collaborators

  • Nune Eye Hospital, Seoul, Korea

    lead OTHER

Principal Investigators

  • Oh Woong Kwon, MD PhD · Nune Eye Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2018-06-30
Completion
2018-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03475407 on ClinicalTrials.gov